Most commonly associated with medical diagnostics, biomarkers indicate the presence of disease as well as determine its stage of progression. However, in addition to their role in detecting illness, biomarkers have important roles to play in other important biological and biochemical functions that are directly relevant to health, including predicting a drug′s toxicity or effectiveness, and providing a reliable parameter with which to measure one′s exposure to hazards in the environment.
A robust introduction to these versatile tools, this book covers the basic fundamentals of biomarkers with discussion of their various uses, then explores the different approaches that can be applied in identifying, characterizing, and monitoring them. A solid foundation for examining the principles, advantages, disadvantages, and applications of methods for biomarker discovery techniques, this book:
- Describes classical and novel biomarkers for different organ damage and disease states including HIV, cancer, neurodegenerative disease, kidney and vascular injury
- Emphasizes the preclinical and clinical manifestations of injury and disease processes and how these can be predicted and monitored with biomarkers
- Covers the approaches, diagnostics, and assays for detecting biomarkers
- Provides information on the U.S. FDA′s Critical Path Initiative, which has placed a high priority on the identification and qualification of additional biomarkers
Biomarkers offers a wealth of material that will aid researchers in choosing the correct biomarker for a given case, teach them how to accurately analyze and interpret their results, and guide them in making informed decisions concerning diagnoses and monitoring of tissue injury. For these reasons, students and professionals from many scientific fields will find Biomarkers a valuable addition to their reference library.
1 Biomarkers: An Evolutionary Perspective (Michael Ferguson and Vishal Vaidya).
SECTION I: TOOLS FOR BIOMARKER DISCOVERY.
2 Genomics (Weida Tong and Donna L. Mendrick).
3 Proteomics for Biomarker Discovery (Timothy D. Veenstra).
4 Metabolic Profiling for Biomarker Discovery (Hector C. Keun).
5 The Bittersweet Promise of Glycobiology (Padmaparna Chaudhuri, Rania Harfouche, and Shiladitya Sengupta).
SECTION II: BIOMARKERS OF INJURY/DISEASE.
6 Biomarkers of Alzheimer′s and Parkinson′s Disease (Walter Maetzler and Daniela Berg).
7 Biomarkers of Cardiac Injury (Anthony S. McLean and Stephen J. Huang).
8 Lung Injury Biomarkers (Urmila P. Kodavanti).
9 Translational Biomarkers of Acute Drug–Induced Liver Injury: The Current State, Gaps and Future Opportunities (Josef Ozer, William Reagan, Sheli Schomaker, Joe Palandra, Mike Baratta and Shashi Ramaiah).
10 Biomarkers of Acute Kidney Injury (Frank Dieterle and Frank Sistare).
11 In Search of Biomarkers for Drug–Induced Vascular Injury (James R. Turk).
12 Biomarkers of Immunotoxicity (Rodney R. Dietert).
13 Biomarkers in Obstetric Medicine (Manish Maski, Sarosh Rana and S. Ananth Karumanchi.
14 Biomarkers in Cancer (Roopali Roy, Christine M. Coticchia, Jiang Yang and Marsha A. Moses).
15 Biomarkers of HIV (Lewis Kaufman and Michael J Ross).
16 Biomarkers of In Vitro Drug–Induced Mitochondrial Dysfunction (James A. Dykens and Yvonne Will).
SECTION III: TECHNOLOGY FOR BIOMARKER DETECTION.
17 Immunoassay–Based Technologies for the Measurement of Biological Materials Used for Biomarkers Discovery and Translational Research (Vincent Ricchiuti).
18 Nanoscale Techniques for Biomarker Quantification (Madhukar Varshney, and Harold G. Craighead).
19 Immunodiagnostics with a Focus on Lateral Flow Point–of–Care Devices (Roy R. Mondesire, Glen M. Ford, Hannie F. Ford, and Stephen C. Mefferd).
SECTION IV: HOT TOPICS IN BIOMARKER RESEARCH.
20 Biomarkers for Environmental Exposure (Jane E. Gallagher, Elaine A. Cohen Hubal and Stephen W. Edwards).
21 Clinical Study Design in Biomarker Research (Orfeas Liangos and Bertrand L. Jaber).
22 Statistical Issues in Biomarker Research (Daniel Holder and Matthew Schipper).
23 Regulatory Perspective for Biomarker Qualification from U.S. FDA (Federico Goodsaid).
24 The European Medicines Agency Approach (Marisa Papaluca Amati and Spiros Vamvakas).